Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $4.52 million. The enterprise value is $1.24 million.

Market Cap	4.52M
Enterprise Value	1.24M

Important Dates

The last earnings date was Monday, March 10, 2025, after market close.

Earnings Date	Mar 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 6.60 million shares outstanding. The number of shares has increased by 294.83% in one year.

Current Share Class	6.60M
Shares Outstanding	6.60M
Shares Change (YoY)	+294.83%
Shares Change (QoQ)	+56.24%
Owned by Insiders (%)	0.83%
Owned by Institutions (%)	3.18%
Float	6.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.16
P/TBV Ratio	1.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.44

Current Ratio	5.44
Quick Ratio	4.63
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-221.65

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-106.08%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-121.98%
Revenue Per Employee	n/a
Profits Per Employee	-$603,848
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -90.11% in the last 52 weeks. The beta is -0.19, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.19
52-Week Price Change	-90.11%
50-Day Moving Average	0.88
200-Day Moving Average	1.68
Relative Strength Index (RSI)	32.70
Average Volume (20 Days)	123,660

Short Selling Information

The latest short interest is 358,637, so 5.44% of the outstanding shares have been sold short.

Short Interest	358,637
Short Previous Month	120,915
Short % of Shares Out	5.44%
Short % of Float	5.57%
Short Ratio (days to cover)	1.75

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.21M
Pretax Income	-9.95M
Net Income	-4.23M
EBITDA	-4.16M
EBIT	-4.21M
Earnings Per Share (EPS)	-$1.61

Full Income Statement

Balance Sheet

The company has $3.36 million in cash and n/a in debt, giving a net cash position of $3.36 million or $0.51 per share.

Cash & Cash Equivalents	3.36M
Total Debt	n/a
Net Cash	3.36M
Net Cash Per Share	$0.51
Equity (Book Value)	3.45M
Book Value Per Share	0.60
Working Capital	3.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$7.31 million and capital expenditures -$90,000, giving a free cash flow of -$7.40 million.

Operating Cash Flow	-7.31M
Capital Expenditures	-90,000
Free Cash Flow	-7.40M
FCF Per Share	-$1.12

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-294.83%
Shareholder Yield	-294.83%
Earnings Yield	-91.84%
FCF Yield	-160.70%

Analyst Forecast

The average price target for Alzamend Neuro is $20.00, which is 2,819.28% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.00
Price Target Difference	2,819.28%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	27.15%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 16, 2024. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Jul 16, 2024
Split Type	Reverse
Split Ratio	0.1:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1